Psych News Alert

​CBD No More Effective Than Placebo for Behavioral Disorders in Kids With Intellectual Disability

Written by Psychiatric News Alert | 11/18/26, 7:31 PM
Children and adolescents who have an intellectual disability and exhibit severe behavioral problems do not appear to benefit from cannabidiol (CBD), according to a report in JAMA Pediatrics.
 
Why It’s Relevant
Children and adolescents with an intellectual disability (ID) frequently experience severe behavioral problems, such as irritability, aggression, and self-injury, which are challenging to treat and contribute to reduced quality of life. While antipsychotics, psychostimulants, and antidepressants are commonly prescribed for such patients, they have limited efficacy and carry a risk of adverse effects. CBD has been proposed as a treatment because of its anxiolytic effects and generally good safety profile; small trials in youth with autism have produced mixed results, but there have been no trials specifically focused on children with ID.
 
By the Numbers
  • A total of 131 children with ID and severe behavioral problems (average age 11, 75% male) were randomized to receive 10mg/kg per day of CBD (n=65) or placebo (n=66) for eight weeks.
  • At end of treatment, average scores on the Aberrant Behavior Checklist—Irritability were similar for both groups—21.7 in the cannabidiol group and 19.2 in the placebo group.
  • Subgroup analyses by autism diagnosis, concomitant psychotropic medications, and severity of symptoms did not reveal any benefit for CBD.
  • The proportion of participants who experienced at least one adverse event were similar for both groups—63.1% in the CBD group and 60.6% in the placebo group.
The Other Side
The study used a fixed dose of 10mg/kg per day based on previous studies in epilepsy, but effects on behavior might have been seen if a lower dose was used. Additionally, though subgroup analyses did not show a benefit for CBD, there might have been benefits seen in other subgroups the study was not designed to assess.
 
Takeaway Message
These findings do not support use of CBD in this population and are important given that CBD is an expensive medication that can interact with numerous drugs—including several psychotropics.
 
Related Information
“Be Prepared to Discuss CBD Products With Patients”
 
Source
Daryl Efron, et. al. Cannabidiol for severe behavioral problems in youths with intellectual disability: a randomized clinical trial. JAMA Pediatrics. Published November 16, 2026. doi:10.1001/jamapediatrics.2026.5152
 
(Image: Getty Images/iStock/panida wijitpanya)